FDA approves AstraZeneca’s Imfinzi to treat LS-SCLC
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody, Imfinzi (durvalumab), to ...
The Pharma Letter7d
Imfinzi first immunotherapy to win LS-SCLC nod
AstraZeneca’s Imfinzi (durvalumab) has been approved in the USA for the treatment of adults with limited-stage small cell ...
Cancer Therapy Advisor6d
Imfinzi Approved as Consolidation in LS-SCLC
The FDA has approved Imfinzi (durvalumab) to treat LS-SCLC that has not progressed after concurrent platinum-based chemotherapy and radiation.
AstraZeneca’s Imfinzi approved in U.S. as immunotherapy regimen for LS-SCLC
Imfinzi has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer, LS-SCLC ...
Yahoo Finance7d
FDA approves AstraZeneca’s Imfinzi to treat LS-SCLC
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody, Imfinzi (durvalumab), to treat limited-stage small cell lung cancer (LS-SCLC) in the adult population.
pharmaphorum7d
FDA clears AZ's Imfinzi for aggressive lung cancer
Imfinzi is already approved for extensive-stage SCLC based on the results of the CASPIAN trial, as well as for locally ...
WebMD3d
FDA Approves Drug for Aggressive Small-Cell Lung Cancer
The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the same ...
Medscape7d
FDA Approves Durvalumab for Limited-Stage SCLC
Durvalumab was associated with a 27% reduction in the risk for death compared with placebo in the phase 3 ADRIATIC trial.
FiercePharma7d
AstraZeneca scores FDA nod for Imfinzi as first immunotherapy for limited-stage small cell lung cancer
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...